StockData
Integrated BioPharma Inc logo

Integrated BioPharma Inc (INBP) stock

INBPOTCPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.18+0.00 (0.00%)

Close on Oct 19, 2026Market cap $5.59MP/E –Yield –

Integrated BioPharma gross margin

Gross margin is gross profit as a percentage of revenue.

Integrated BioPharma's gross margin for the twelve months ending Jun 30, 2026 was 1.8%. For fiscal 2026 it was 1.8%, against 10.2% the year before. The highest annual figure on record is 25.0% in fiscal 2011.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2026Jun 30, 20261.8%−8.4
FY2025Jun 30, 202510.2%+2.5
FY2024Jun 30, 20247.7%−0.3
FY2023Jun 30, 20238.0%−3.6
FY2022Jun 30, 202211.6%−3.3
FY2021Jun 30, 202114.9%+2.2
FY2020Jun 30, 202012.7%+0.3
FY2019Jun 30, 201912.4%+1.0
FY2018Jun 30, 201811.4%−2.8
FY2017Jun 30, 201714.2%+1.2
FY2016Jun 30, 201613.0%+1.3
FY2015Jun 30, 201511.7%−2.8
FY2014Jun 30, 201414.5%−1.9
FY2013Jun 30, 201316.4%−4.4
FY2012Jun 30, 201220.8%−4.2
FY2011Jun 30, 201125.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q4 FY2026CQ2 2026Jun 30, 20260.3%−10.1
Q3 FY2026CQ1 2026Mar 31, 2026-2.7%−13.9
Q2 FY2026CQ4 2025Dec 31, 20250.3%−9.0
Q1 FY2026CQ3 2025Sep 30, 20258.0%−2.0
Q4 FY2025CQ2 2025Jun 30, 202510.4%+0.3
Q3 FY2025CQ1 2025Mar 31, 202511.1%+1.6
Q2 FY2025CQ4 2024Dec 31, 20249.3%+4.8
Q1 FY2025CQ3 2024Sep 30, 202410.1%+3.6
Q4 FY2024CQ2 2024Jun 30, 202410.1%+2.5
Q3 FY2024CQ1 2024Mar 31, 20249.5%+1.8
Q2 FY2024CQ4 2023Dec 31, 20234.5%−4.2
Q1 FY2024CQ3 2023Sep 30, 20236.4%−1.6
Q4 FY2023CQ2 2023Jun 30, 20237.6%−2.9
Q3 FY2023CQ1 2023Mar 31, 20237.7%−5.0
Q2 FY2023CQ4 2022Dec 31, 20228.7%−3.3
Q1 FY2023CQ3 2022Sep 30, 20228.1%−3.1
Q4 FY2022CQ2 2022Jun 30, 202210.5%−2.8
Q3 FY2022CQ1 2022Mar 31, 202212.7%−2.9
Q2 FY2022CQ4 2021Dec 31, 202112.0%−3.3
Q1 FY2022CQ3 2021Sep 30, 202111.2%−4.5
Q4 FY2021CQ2 2021Jun 30, 202113.3%+2.6
Q3 FY2021CQ1 2021Mar 31, 202115.6%+2.0
Q2 FY2021CQ4 2020Dec 31, 202015.2%+1.0
Q1 FY2021CQ3 2020Sep 30, 202015.6%+3.4
Q4 FY2020CQ2 2020Jun 30, 202010.7%−0.9
Q3 FY2020CQ1 2020Mar 31, 202013.6%−1.3
Q2 FY2020CQ4 2019Dec 31, 201914.3%+3.2
Q1 FY2020CQ3 2019Sep 30, 201912.3%+0.4
Q4 FY2019CQ2 2019Jun 30, 201911.6%−0.0
Q3 FY2019CQ1 2019Mar 31, 201914.9%+1.0
Q2 FY2019CQ4 2018Dec 31, 201811.1%+1.4
Q1 FY2019CQ3 2018Sep 30, 201811.8%+1.5
Q4 FY2018CQ2 2018Jun 30, 201811.7%−3.5
Q3 FY2018CQ1 2018Mar 31, 201813.9%+1.3
Q2 FY2018CQ4 2017Dec 31, 20179.7%−2.2
Q1 FY2018CQ3 2017Sep 30, 201710.3%−6.7
Q4 FY2017CQ2 2017Jun 30, 201715.2%–
Q3 FY2017CQ1 2017Mar 31, 201712.6%–
Q2 FY2017CQ4 2016Dec 31, 201611.9%–
Q1 FY2017CQ3 2016Sep 30, 201617.0%–

More Integrated BioPharma figures

See a number that looks wrong?